SOCS6 and prostate cancer: Suppression of SOCS-6 (an inhibitor of cytokine-6 signaling) correlated with malignant progression of human prostate cancer, and it was associated with late clinical stage (p = 0.029) and metastasis in the LN (p = 0.013).